ORGN vs VVOS

For growth investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger pick with 8. 9% revenue growth year-over-year, versus 8. 6% for Origin Materials, Inc. (ORGN). Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Origin Materials, Inc.

(ORGN) delivered a total return of -99. 5%, compared to -99. 6% for Vivos Therapeutics, Inc. (VVOS). Over 10 years, the gap is even starker: ORGN returned -99. 5% versus VVOS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.

(VVOS) is the lower-risk stock at 0. 74β versus Origin Materials, Inc. 's 1. 68β — meaning ORGN is approximately 128% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Origin Materials, Inc. (ORGN) carries a lower debt/equity ratio of 3% versus 19% for Vivos Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vivos Therapeutics, Inc.

(VVOS) is pulling ahead at 8. 9% versus 8. 6% for Origin Materials, Inc. (ORGN). On earnings-per-share growth, the picture is similar: Vivos Therapeutics, Inc. grew EPS 80. 1% year-over-year, compared to -441. 2% for Origin Materials, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vivos Therapeutics, Inc.

(VVOS) is the more profitable company, earning -74. 1% net margin versus -267. 6% for Origin Materials, Inc. — meaning it keeps -74. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VVOS leads at -74. 3% versus -271. 3% for ORGN. At the gross margin level — before operating expenses — VVOS leads at 60. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74)). Origin Materials, Inc. (ORGN) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VVOS: -99. 7%, ORGN: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ORGN (Basic Materials) and VVOS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.